From GPAINNOVA we are leading the RESPIRA project to help respond to the global health crisis with the creation of the new RESPIRA emergency ventilator, which is in great need globally due to the Covid-19 pandemic.
The RESPIRA device, which we have created in record time, already has the approval of the Spanish Agency for Medicines and Health Products (AEMPS) of the Spanish Ministry of Health to be used with patients affected by Covid-19 in 45 hospitals and has obtained Excellent results at the prestigious Hospital Clínic in Barcelona, the project's healthcare center.
The RESPIRA device can be manufactured for any country in the world and thus extend its use to more hospitals with patients affected by Covid-19, with the due authorization of their health authorities. GPAINNOVA has accelerated the production of the RESPIRA device to be able to supply administrations and individuals quickly and efficiently, at a production rate of around 800 units per week.
We are willing to deliver the RESPIRA device to hospitals in as many areas as possible to assist in this health emergency. For this reason, GPAINNOVA has joined the campaign CORONAVIRUS RESPONSE led by the Hospital Clinic with the aim of encouraging companies and individuals to make solidarity financial contributions, through the Clinic Foundation for Biomedical Research at Hospital Clinic, so that GPAINNOVA produces devices and distribute or order devices from us so that you can distribute them to health centers that may need them.
A project committed to maximum efficiency in record time
In order to understand the scope of the project, it is important to take into account the need and urgency of the situation in health centers that have required solutions to care for patients.
The following describes the development of the project where you can clearly see the efficiency of the process of this project in which the commitment of all its members has been key.
03/23/2020 - 03/29/2020
Work meeting. Defined concept.
3D design and defined components, First working meeting with Health Consortium.
First version of Software developed.
Presentation of the RESPIRA prototype at Hospital Clínic de Barcelona.
On-site work at Hospital Clínic, SW development, ventilation curves, design improvements.
Animal test carried out at the CMCiB of the Germans Trias i Pujol Research Institute.
In-vitro test at Hospital Clínic de Barcelona.
Approval of the Clinical Research Ethics Committee of the Clinical Hospital for the human trial.
Documentation sent to AEMPS. Including electrical safety, functionality and EMC tests.
03/30/2020 - 04/05/2020
04/06/2020 - 04/12/2020
Approval for human testing by AEMPS.
AEMPS amendment for the unique ICU in Catalonia, made up of 45 hospitals, and approval for adherence to the clinical study by any Spanish healthcare center.
First trial with patient.
Second trial with patient.
Sending the report to the AEMPS.
Start of processing the CE marking.
Sending of the first 100 units to the Catalan Emergency Medical Service (SEM).
Agreement with Hospital Clínic for World ICU, for the trial with RESPIRA devices .